Literature DB >> 33175256

Spinocerebellar ataxia type 23 (SCA23): a review.

Fan Wu1, Xu Wang1, Xiaohan Li1, Huidi Teng1, Tao Tian2, Jing Bai3.   

Abstract

Spinocerebellar ataxias (SCAs), formerly known as autosomal dominant cerebellar ataxias (ADCAs), are a group of hereditary heterogeneous neurodegenerative diseases. Gait, progressive ataxia, dysarthria, and eye movement disorder are common symptoms of spinocerebellar ataxias. Other symptoms include peripheral neuropathy, cognitive impairment, psychosis, and seizures. Patients may lose their lives due to out of coordinated respiration and/or swallowing. Neurological signs cover pyramidal or extrapyramidal signs, spasm, ophthalmoplegia, hyperactive deep tendon reflexes, and so on. Different subtypes of SCAs present various clinical features. Spinocerebellar ataxia type 23 (SCA23), one subtype of the SCA family, is characterized by mutant prodynorphin (PDYN) gene. Based on literatures, this review details a series of SCA23, to improve a whole understanding of clinicians and point out the potential research direction of this dysfunction, including a history, pathophysiological mechanism, diagnosis and differential diagnosis, epigenetics, penetrance and prevalence, genetic counseling, treatment and prognosis.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Clinical symptoms; Epigenetics; Pathophysiological mechanisms; Prodynorphin; Spinocerebellar ataxia type 23; Spinocerebellar ataxias

Mesh:

Year:  2020        PMID: 33175256     DOI: 10.1007/s00415-020-10297-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  94 in total

1.  Molecular genetic analysis of a new form of spinocerebellar ataxia in a Chinese Han family.

Authors:  Yuan Yuan; Xin Zhou; Feng Ding; Yumin Liu; Jiancheng Tu
Journal:  Neurosci Lett       Date:  2010-08-02       Impact factor: 3.046

2.  Classification of the hereditary ataxias and paraplegias.

Authors:  A E Harding
Journal:  Lancet       Date:  1983-05-21       Impact factor: 79.321

Review 3.  Spinocerebellar ataxia type 20.

Authors:  Elsdon Storey; R J McKinlay Gardner
Journal:  Handb Clin Neurol       Date:  2012

4.  A 7.5-Mb duplication at chromosome 11q21-11q22.3 is associated with a novel spastic ataxia syndrome.

Authors:  Janel O Johnson; Giovanni Stevanin; Joyce van de Leemput; Dena G Hernandez; Sampath Arepalli; Sylvie Forlani; Reza Zonozi; J Raphael Gibbs; Alexis Brice; Alexandra Durr; Andrew B Singleton
Journal:  Mov Disord       Date:  2014-12-27       Impact factor: 10.338

Review 5.  Mini-review: spinocerebellar ataxias: an update of SCA genes.

Authors:  Alexis Trott; Lucien J Houenou
Journal:  Recent Pat DNA Gene Seq       Date:  2012-08

6.  RNA FISH for detecting expanded repeats in human diseases.

Authors:  Martyna O Urbanek; Wlodzimierz J Krzyzosiak
Journal:  Methods       Date:  2015-11-23       Impact factor: 3.608

Review 7.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

8.  Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3.

Authors:  D S Verbeek; B P van de Warrenburg; P Wesseling; P L Pearson; H P Kremer; R J Sinke
Journal:  Brain       Date:  2004-08-11       Impact factor: 13.501

Review 9.  Hereditary ataxias: overview.

Authors:  Suman Jayadev; Thomas D Bird
Journal:  Genet Med       Date:  2013-03-28       Impact factor: 8.822

Review 10.  Spinocerebellar ataxia: an update.

Authors:  Roisin Sullivan; Wai Yan Yau; Emer O'Connor; Henry Houlden
Journal:  J Neurol       Date:  2018-10-03       Impact factor: 4.849

View more
  1 in total

Review 1.  Epigenetic and Transcriptional Control of the Opioid Prodynorphine Gene: In-Depth Analysis in the Human Brain.

Authors:  Olga Nosova; Igor Bazov; Victor Karpyak; Mathias Hallberg; Georgy Bakalkin
Journal:  Molecules       Date:  2021-06-07       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.